![ISPOR Europe 2024 – May 5-8. Register now.]({"type":"image" , "src" : "/sda/112342/JournalAd-ISPOR-2024-Leaderboard.jpg"})
Citations (47)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (12)
Vishwa Kotak, Nisha Tanna, Mrunali Patel & Rashmin Patel. (2022) Determination of Asenapine Maleate in Pharmaceutical and Biological Matrices: A Critical Review of Analytical Techniques over the Past Decade. Critical Reviews in Analytical Chemistry 52:8, pages 1755-1771.
Read now
Read now
Sharon Taub, Amir Krivoy, Eromona Whiskey & Sukhi S. Shergill. (2022) New approaches to antipsychotic medication adherence – safety, tolerability and acceptability. Expert Opinion on Drug Safety 21:4, pages 517-524.
Read now
Read now
Haruna Matsuzaki, Masakazu Hatano, Miko Iwata & Shigeki Yamada. (2021) Treatment Continuation of Asenapine or Olanzapine in Japanese Schizophrenia Patients: A Propensity Score Matched Study. Neuropsychiatric Disease and Treatment 17, pages 3655-3661.
Read now
Read now
Brennan Carrithers & Rif S El-Mallakh. (2020) Transdermal Asenapine in Schizophrenia: A Systematic Review. Patient Preference and Adherence 14, pages 1541-1551.
Read now
Read now
Akhil Suresh, Reema Narayan & Usha Y Nayak. (2020) Recent advances in the development of asenapine formulations. Expert Opinion on Drug Delivery 17:10, pages 1377-1393.
Read now
Read now
Junqiu Zhai, Yu-e Wang, Xiangping Zhou, Yan Ma & Shixia Guan. (2020) Long-term sustained release Poly(lactic-co-glycolic acid) microspheres of asenapine maleate with improved bioavailability for chronic neuropsychiatric diseases. Drug Delivery 27:1, pages 1283-1291.
Read now
Read now
Donatella Marazziti, Federico Mucci, Valentina Falaschi & Liliana Dell’Osso. (2019) Asenapine for the treatment of bipolar disorder. Expert Opinion on Pharmacotherapy 20:11, pages 1321-1330.
Read now
Read now
Peter Dogterom, Robert Riesenberg, Rik de Greef, Justin Dennie, Martin Johnson, Venkatesh Pilla Reddy, André MM Miltenburg, Robert L Findling, Abhijeet Jakate, Timothy J Carrothers & Matthew D Troyer. (2018) Asenapine pharmacokinetics and tolerability in a pediatric population. Drug Design, Development and Therapy 12, pages 2677-2693.
Read now
Read now
Gina Stassinos & Wendy Klein-Schwartz. (2018) Asenapine, iloperidone and lurasidone exposures in young children reported to U.S. poison centers. Clinical Toxicology 56:5, pages 355-359.
Read now
Read now
Leslie Citrome, Ronald Landbloom, Cheng-Tao Chang & Willie Earley. (2017) Effects of asenapine on agitation and hostility in adults with acute manic or mixed episodes associated with bipolar I disorder. Neuropsychiatric Disease and Treatment 13, pages 2955-2963.
Read now
Read now
Juilee A. Kulkarni & Amelia M. Avachat. (2017) Pharmacodynamic and pharmacokinetic investigation of cyclodextrin-mediated asenapine maleate in situ nasal gel for improved bioavailability. Drug Development and Industrial Pharmacy 43:2, pages 234-245.
Read now
Read now
Leslie Citrome. (2014)
Asenapine review, part II: clinical efficacy, safety and tolerability. Expert Opinion on Drug Safety 13:6, pages 803-830.
Read now
Read now
Articles from other publishers (35)
Shuhei Wada, Kunihiro Iwamoto, Hiroki Okumura, Hirotake Hida, Shuichi Hiraoka, Aya Kamei, Daisuke Mori, Kiyofumi Yamada & Norio Ozaki. (2023) Sensory evaluation of the bitterness of asenapine using D-sorbitol pretreatment: single-blind, placebo-controlled, crossover trial. BMC Psychiatry 23:1.
Crossref
Crossref
George T. Kannarkat, Stanley N. Caroff & James F. Morley. (2022) Risk of Drug-induced Movement Disorders with Newer Antipsychotic Agents. Tremor and Other Hyperkinetic Movements 12:1.
Crossref
Crossref
Frank M. Schmidt. 2020. NeuroPsychopharmacotherapy. NeuroPsychopharmacotherapy
1
8
.
Peter Schönknecht. 2020. NeuroPsychopharmacotherapy. NeuroPsychopharmacotherapy
1
10
.
Frank M. Schmidt. 2022. NeuroPsychopharmacotherapy. NeuroPsychopharmacotherapy
1575
1582
.
Hubertus Himmerich & Amy Hamilton. 2022. NeuroPsychopharmacotherapy. NeuroPsychopharmacotherapy
1447
1467
.
Peter Schönknecht. 2022. NeuroPsychopharmacotherapy. NeuroPsychopharmacotherapy
1871
1879
.
Przemysław J. Danek & Władysława A. Daniel. (2021) Long-Term Treatment with Atypical Antipsychotic Iloperidone Modulates Cytochrome P450 2D (CYP2D) Expression and Activity in the Liver and Brain via Different Mechanisms. Cells 10:12, pages 3472.
Crossref
Crossref
Przemysław J. Danek, Ewa Bromek, Anna Haduch & Władysława A. Daniel. (2021) Chronic treatment with asenapine affects cytochrome P450 2D (CYP2D) in rat brain and liver. Pharmacological aspects. Neurochemistry International 151, pages 105209.
Crossref
Crossref
Mehak Pahwa, Ahmad Sleem, Omar H. Elsayed, Megan Elizabeth Good & Rif S. El-Mallakh. (2021) New Antipsychotic Medications in the Last Decade. Current Psychiatry Reports 23:12.
Crossref
Crossref
Jonathan M. Meyer & Stephen M. Stahl. 2021. The Clinical Use of Antipsychotic Plasma Levels. The Clinical Use of Antipsychotic Plasma Levels
337
371
.
Ann Kathleen Sheehan, Christopher Richards-Bentley, Raed J. Hawa & Joseph J. Rasimas. (2021) Case report: asenapine and anticholinergic toxicity. International Clinical Psychopharmacology 36:4, pages 214-217.
Crossref
Crossref
Meghan Musselman, Justin Faden & Leslie Citrome. (2021) Asenapine: an atypical antipsychotic with atypical formulations. Therapeutic Advances in Psychopharmacology 11, pages 204512532110352.
Crossref
Crossref
Przemysław J. Danek, Jacek Wójcikowski & Władysława A. Daniel. (2020) Asenapine and iloperidone decrease the expression of major cytochrome P450 enzymes CYP1A2 and CYP3A4 in human hepatocytes. A significance for drug-drug interactions during combined therapy. Toxicology and Applied Pharmacology 406, pages 115239.
Crossref
Crossref
Jyothsna Manikkath, Harendra S. Parekh & Srinivas Mutalik. (2020) Surface-engineered nanoliposomes with lipidated and non-lipidated peptide-dendrimeric scaffold for efficient transdermal delivery of a therapeutic agent: Development, characterization, toxicological and preclinical performance analyses. European Journal of Pharmaceutics and Biopharmaceutics 156, pages 97-113.
Crossref
Crossref
Felice Iasevoli, Elisabetta Filomena Buonaguro, Camilla Avagliano, Annarita Barone, Anna Eramo, Licia Vellucci & Andrea de Bartolomeis. (2020) The Effects of Antipsychotics on the Synaptic Plasticity Gene Homer1a Depend on a Combination of Their Receptor Profile, Dose, Duration of Treatment, and Brain Regions Targeted. International Journal of Molecular Sciences 21:15, pages 5555.
Crossref
Crossref
Santosh Ashok Kumbhar, Chandrakant R. Kokare, Birendra Shrivastava, Bapi Gorain & Hira Choudhury. (2020) Preparation, characterization, and optimization of asenapine maleate mucoadhesive nanoemulsion using Box-Behnken design: In vitro and in vivo studies for brain targeting. International Journal of Pharmaceutics 586, pages 119499.
Crossref
Crossref
Jacek Wójcikowski, Przemysław J. Danek, Agnieszka Basińska-Ziobroń, Renata Pukło & Władysława A. Daniel. (2020) In vitro inhibition of human cytochrome P450 enzymes by the novel atypical antipsychotic drug asenapine: a prediction of possible drug–drug interactions. Pharmacological Reports 72:3, pages 612-621.
Crossref
Crossref
Renuka S. Managuli, Julie Tzu-Wen Wang, Farid Muhammad Faruqu, Abhjieet Pandey, Sanyog Jain, Khuloud T. Al-Jamal & Srinivas Mutalik. (2020) Surface engineered nanoliposomal platform for selective lymphatic uptake of asenapine maleate: In vitro and in vivo studies. Materials Science and Engineering: C 109, pages 110620.
Crossref
Crossref
Nicolo Milani, NaHong Qiu, Birgit Molitor, Justine Badée, Gabriele Cruciani & Stephen Fowler. (2020) Use of Phenotypically Poor Metabolizer Individual Donor Human Liver Microsomes To Identify Selective Substrates of UGT2B10. Drug Metabolism and Disposition 48:3, pages 176-186.
Crossref
Crossref
P. Danek & W.A. Daniel. (2020) P.103 The effect of chronic treatment with the asenapine on the cytochrome P450 2D (CYP2D) activity in different brain areas. European Neuropsychopharmacology 31, pages S2-S3.
Crossref
Crossref
Hubertus Himmerich & Amy Hamilton. 2020. NeuroPsychopharmacotherapy. NeuroPsychopharmacotherapy
1
21
.
Leslie Citrome & Jan Volavka. 2020. Violence and Mental Disorders. Violence and Mental Disorders
253
268
.
Jyothsna Manikkath, Gautham G. Shenoy, Sureshwar Pandey & Srinivas Mutalik. (2019) Response Surface Methodology for Optimization of Ultrasound-Assisted Transdermal Delivery and Skin Retention of Asenapine Maleate. Journal of Pharmaceutical Innovation 14:4, pages 391-399.
Crossref
Crossref
Kohei Takahashi, Osamu Nakagawasai, Wakana Sakuma, Wataru Nemoto, Takayo Odaira, Jia-Rong Lin, Hiroshi Onogi, Lalit K. Srivastava & Koichi Tan-No. (2019) Prenatal treatment with methylazoxymethanol acetate as a neurodevelopmental disruption model of schizophrenia in mice. Neuropharmacology 150, pages 1-14.
Crossref
Crossref
Massimo Carlo Mauri, Silvia Paletta, Chiara Di Pace, Alessandra Reggiori, Giovanna Cirnigliaro, Isabel Valli & Alfredo Carlo Altamura. (2018) Clinical Pharmacokinetics of Atypical Antipsychotics: An Update. Clinical Pharmacokinetics 57:12, pages 1493-1528.
Crossref
Crossref
Ekaterina Stepanova, Bradley Grant & Robert L. Findling. (2017) Asenapine Treatment in Pediatric Patients with Bipolar I Disorder or Schizophrenia: A Review. Pediatric Drugs 20:2, pages 121-134.
Crossref
Crossref
Sanjay Kumar Singh, Mahendra Kumar Hidau, Shrikant Gautam, Kiran Gupta, Krishna Pal Singh, Shio Kumar Singh & Sanjay Singh. (2018) Glycol chitosan functionalized asenapine nanostructured lipid carriers for targeted brain delivery: Pharmacokinetic and teratogenic assessment. International Journal of Biological Macromolecules 108, pages 1092-1100.
Crossref
Crossref
Eduard Vieta & José Manuel Montes. (2017) A Review of Asenapine in the Treatment of Bipolar Disorder. Clinical Drug Investigation 38:2, pages 87-99.
Crossref
Crossref
Peter SturmeyLeslie Citrome & Jan Volavka. 2017. The Wiley Handbook of Violence and Aggression. The Wiley Handbook of Violence and Aggression
1
15
.
Leslie Citrome. 2017. The Diagnosis and Management of Agitation. The Diagnosis and Management of Agitation
200
218
.
Greg L. Plosker & Emma D. Deeks. (2016) Asenapine: A Review in Schizophrenia. CNS Drugs 30:7, pages 655-666.
Crossref
Crossref
Toshihiko Kinoshita, Ya-Mei Bai, Jong-Hoon Kim, Mutsuo Miyake & Nobuyuki Oshima. (2016) Efficacy and safety of asenapine in Asian patients with an acute exacerbation of schizophrenia: a multicentre, randomized, double-blind, 6-week, placebo-controlled study. Psychopharmacology 233:14, pages 2663-2674.
Crossref
Crossref
Leslie Citrome & Jan Volavka. (2015) Preventing Violence in Patients with Schizophrenia. Current Treatment Options in Psychiatry 2:2, pages 182-191.
Crossref
Crossref
Xinhui Lim, Prashant Tibrewal, Rohan Dhillon, Tarun Bastiampillai, Linda Chen & Andrew Lin. (2015) Can asenapine cause myocarditis?. Asian Journal of Psychiatry 14, pages 78-79.
Crossref
Crossref